BR9607614A - Uso de compostos específicos para sh2 de lck para tratar doenças autoimunes e rejeição ao aloenxerto - Google Patents
Uso de compostos específicos para sh2 de lck para tratar doenças autoimunes e rejeição ao aloenxertoInfo
- Publication number
- BR9607614A BR9607614A BR9607614A BR9607614A BR9607614A BR 9607614 A BR9607614 A BR 9607614A BR 9607614 A BR9607614 A BR 9607614A BR 9607614 A BR9607614 A BR 9607614A BR 9607614 A BR9607614 A BR 9607614A
- Authority
- BR
- Brazil
- Prior art keywords
- lck
- autoimmune diseases
- specific compounds
- allograft rejection
- treat autoimmune
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38638195A | 1995-02-10 | 1995-02-10 | |
US40022095A | 1995-03-07 | 1995-03-07 | |
US49735795A | 1995-06-30 | 1995-06-30 | |
PCT/US1996/001964 WO1996024343A1 (en) | 1995-02-10 | 1996-02-09 | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9607614A true BR9607614A (pt) | 1998-06-09 |
Family
ID=27409758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9607614A BR9607614A (pt) | 1995-02-10 | 1996-02-09 | Uso de compostos específicos para sh2 de lck para tratar doenças autoimunes e rejeição ao aloenxerto |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0809490A4 (pt) |
JP (2) | JPH10513474A (pt) |
KR (1) | KR19980702115A (pt) |
AU (1) | AU4923796A (pt) |
BR (1) | BR9607614A (pt) |
CA (1) | CA2212645A1 (pt) |
FI (1) | FI973259A (pt) |
HU (1) | HUP9802078A3 (pt) |
NO (1) | NO973659L (pt) |
WO (1) | WO1996024343A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922697A (en) * | 1996-10-02 | 1999-07-13 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins |
WO2004085406A1 (en) | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
CN1934092A (zh) | 2004-03-23 | 2007-03-21 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007913A1 (en) * | 1992-09-25 | 1994-04-14 | Warner-Lambert Company | Peptide antagonists of sh2 binding and therapeutic uses thereof |
US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
US5710129A (en) * | 1995-02-23 | 1998-01-20 | Ariad Pharmaceuticals, Inc. | Inhibitors of SH2-mediated processes |
-
1996
- 1996-02-09 KR KR1019970705510A patent/KR19980702115A/ko not_active Application Discontinuation
- 1996-02-09 CA CA002212645A patent/CA2212645A1/en not_active Abandoned
- 1996-02-09 BR BR9607614A patent/BR9607614A/pt not_active Application Discontinuation
- 1996-02-09 AU AU49237/96A patent/AU4923796A/en not_active Abandoned
- 1996-02-09 EP EP96905494A patent/EP0809490A4/en not_active Withdrawn
- 1996-02-09 WO PCT/US1996/001964 patent/WO1996024343A1/en not_active Application Discontinuation
- 1996-02-09 HU HU9802078A patent/HUP9802078A3/hu unknown
- 1996-02-09 JP JP8524486A patent/JPH10513474A/ja active Pending
- 1996-02-12 EP EP96906615A patent/EP0811159A1/en not_active Withdrawn
- 1996-02-12 JP JP8524493A patent/JPH10513564A/ja active Pending
-
1997
- 1997-08-07 FI FI973259A patent/FI973259A/fi unknown
- 1997-08-08 NO NO973659A patent/NO973659L/no unknown
Also Published As
Publication number | Publication date |
---|---|
HUP9802078A2 (hu) | 1998-12-28 |
JPH10513564A (ja) | 1998-12-22 |
KR19980702115A (ko) | 1998-07-15 |
JPH10513474A (ja) | 1998-12-22 |
FI973259A0 (fi) | 1997-08-07 |
HUP9802078A3 (en) | 1999-04-28 |
EP0809490A4 (en) | 1999-10-20 |
WO1996024343A1 (en) | 1996-08-15 |
CA2212645A1 (en) | 1996-08-15 |
AU4923796A (en) | 1996-08-27 |
FI973259A (fi) | 1997-10-08 |
EP0811159A1 (en) | 1997-12-10 |
EP0809490A1 (en) | 1997-12-03 |
NO973659L (no) | 1997-10-08 |
NO973659D0 (no) | 1997-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9612698A (pt) | Composição estável de avidina e processos para uso da mesma | |
BR9611502A (pt) | Uso de epinastina para o tratamento de dor | |
PT1167364E (pt) | Compostos contendo benzopirano e respectivas formas de pro-farmacos | |
PT1445259E (pt) | Utilizacao de formas cristalinas de 2-metil-tieno-benzodiazepina | |
BR9504072A (pt) | Composiçao farmacêutica métodos para o tratamento de hipercolesterolemia de aterosclerose e kit | |
NO964189D0 (no) | Smertestillende og anti-inflammatorisk middel samt fremgangsmåte ved fremstilling derav | |
BR9510229A (pt) | Uso de um derivado 2-alquil ou 2-aralquil-bit e composição | |
FI956339A (fi) | Hypotalaamisen kuukautisten puuttumisen hoitaminen | |
BR9502691A (pt) | Uso de ácido hialurônico e dispositivo protético | |
BR9505382A (pt) | Utilização de ao menos um antagonista de substáncia P | |
BR9604631A (pt) | Compostos bicíclicos aromáticos utilizaçao de compostos composiçao farmacêutica composiçao cosmética e sua utilizaçao | |
AU5637796A (en) | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states | |
EG21286A (en) | Blends of organosillane compounds and their use | |
BR9505381A (pt) | Utilização de ao menos um antagonista de substáncia p e utilização de um antagonista de substáncia p | |
AU2203095A (en) | Apparatus for the sanitary gathering and retention of animal waste for disposal | |
BR9607614A (pt) | Uso de compostos específicos para sh2 de lck para tratar doenças autoimunes e rejeição ao aloenxerto | |
BR9609081A (pt) | Combinações de substáncias ativas | |
BR9611838A (pt) | Compostos úteis para a enibição de replicação de HIV-1 E mutantes de HIV-1 | |
ID18081A (id) | Proses untuk menyiapkan benzotiazepin aktif secara optik dan bahan bantunya | |
BR9703499A (pt) | Emprego de derivados de teofilina para o tratamento e profilaxia de estados de choque novos compostos de xantina e processo para a sua preparação | |
BR9610314A (pt) | Imunossupressor processos para prevenir ou tratar doenças autoimunes em mamíferos e prevenir rejeição de enxerto uso de um composto composição farmacêutica e uso da mesma | |
ZA961318B (en) | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection | |
AU2845897A (en) | Photosensitive elements and their process of use | |
ITTO910923A0 (it) | Procedimento di degradazione biologica di grassi e di rifiuti grassi | |
ITMI922142A0 (it) | Procedimento di selezione e raccolta separata di rifiuti solidi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law |